Для корректного отображения сайта воспользуйтесь другим бразуером
23 October 2026
A Joint Meeting of the Working Group on Healthcare and Pharmaceutical Industry Development of the Foreign Investors’ Council under the President of the Republic of Kazakhstan Was Held

On 23 October 2026, a working meeting of the Working Group on Healthcare and Pharmaceutical Industry Development of the Foreign Investors’ Council under the President of the Republic of Kazakhstan (FIC) was held.

The Kazakhstani side was represented by Akmaral Alnazarova, Minister of Healthcare of the Republic of Kazakhstan and Kazakhstani Co-Chair of the FIC Working Group on Healthcare and Pharmaceutical Industry Development, as well as:

  • Nurkan Sadvakassov — Acting Chairman of the Committee for Sanitary and Epidemiological Control, Ministry of Healthcare of the Republic of Kazakhstan;
  • Gaukhar Raimkulova — Deputy Chair of the Committee for Pharmaceutical Control, Ministry of Healthcare of the Republic of Kazakhstan;
  • Aslan K in ayatov — Director of the Department for the Development of the Pharmaceutical and Medical Industries, Ministry of Healthcare of the Republic of Kazakhstan;
  • Ulmira Nuralieva — Deputy Director of the Department of Science and Human Resources;
  • Samat Ramazanov — Managing Director of SK-Pharmacy LLP.

The foreign side was represented by:

  • Adam Aleksejuk — General Director of SANTO, a member of the Polpharma Group, Central Asia (Khimpharm JSC), and Foreign Co-Chair of the FIC Working Group on Healthcare and Pharmaceutical Industry Development;
  • Zhanna Baidasheva — Director of the Kazakhstan Foreign Investors’ Council Association;
  • Elmira Pistayeva — Senior Adviser for Government Relations, Kazakhstan Foreign Investors’ Council Association;
  • Yaroslavna Budach — Director of Research and Development, Polpharma Group;
  • Askhat Mubarakov — Market Access Manager, Khimpharm JSC (SANTO, a member of the Polpharma Group).

The meeting addressed key items on the Working Group’s agenda, including the regulation of medicine prices, accelerated registration of medicines, technology transfer, quality control of dietary supplements, and human capital development in the pharmaceutical industry.

The parties emphasized the importance of continued constructive dialogue between government authorities and foreign investors and reaffirmed their commitment to further cooperation aimed at ensuring access to quality medicines and developing domestic pharmaceutical manufacturing in accordance with the legislation of the Republic of Kazakhstan.

Share: